Employers can improve the return on their investment by holding partners accountable for measurable outcomes and ensuring members receive the support needed to sustain results
1 ), T4 is an excellent candidate for the treatment of demyelinating diseases also based on data demonstrating safety, tolerability and efficacy of T4 in clinical practice (Crockford, 2007, Vasilopoulou et al., 2015, Marks and Kumar, 2016)
The most common adverse effects are gastrointestinal , including nausea, vomiting, diarrhoea, and constipation
Phase 2 (Jastreboff et al., NEJM 2023) reported 24.2% weight loss at 48 weeks at 12 mg
NOT Appropriate for Acute Injuries Requiring Medical Intervention: Fractures, severe sprains, traumatic injuries, and conditions requiring immediate medical attention should be evaluated and treated by healthcare professionals